Skip to main content
SpringerLink
Log in

Obesity medication-related ADEs differ between drug classes

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication Journal of Global Health : 1 Sep 2023. Available from: URL: https://doi.org/10.7189/jogh.13.04095

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Obesity medication-related ADEs differ between drug classes. Reactions Weekly 1973, 10 (2023). https://doi.org/10.1007/s40278-023-45738-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-45738-3

Search

Navigation